MB 102

Drug Profile

MB 102

Alternative Names: Anti-CD123 chimeric antigen receptor T cell therapy - Mustang Bio; CD123 CAR T; MB 102 - Mustang Bio; MB102

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Mustang Bio
  • Class CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 19 Jul 2018 Mustang Bio plans a phase I/II trial of MB 102 in Acute myeloid leukaemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome (MDS) in 2019
  • 19 Jul 2018 Mustang Bio completes pre-IND meeting with US FDA for Acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndrome (MDS)
  • 22 Jun 2018 Mustang Bio announces intention to submit IND application to US FDA for Acute myeloid leukaemia and Blastic plasmacytoid dendritic cell neoplasm in late 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top